Private company

Cyteir Therapeutics, Inc.

American pharmaceutical preparations company, incorporated in Delaware1

In its 2023 annual report the company says: “We are a clinical-stage biotechnology company focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.”57 It is headquartered in Stoneham, Massachusetts.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersStoneham, Massachusetts1
  • Incorporated inDE2
  • Business addressP.O. Box 80084, Stoneham, Ma 021802
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income34-$48.2M in 2022+130% since 2020
-$60.0M-$40.0M-$20.0M02020: -$20.9M-$20.9M20202021: -$42.3M-$42.3M2021+102%2022: -$48.2M-$48.2M2022+14%
Net income34-$46.1M in 2022+121% since 2020
-$60.0M-$40.0M-$20.0M02020: -$20.8M-$20.8M20202021: -$42.1M-$42.1M2021+102%2022: -$46.1M-$46.1M2022+9%
Fiscal year20192020202120222023
Research and development$16.8M3$31.0M4$34.6M4
Operating expenses$42.3M4$48.2M4
Operating income-$20.9M3-$42.3M4-$48.2M4
Income before tax-$42.1M4-$46.0M4
Net income-$20.8M3-$42.1M4-$46.1M4
Earnings per share-$2.164-$1.314
Earnings per share (diluted)-$2.164-$1.314
Shares (weighted, basic)19.5M shares435.3M shares4
Shares (weighted, diluted)19.5M shares435.3M shares4

Compare Cyteir Therapeutics, Inc. with another company

Corporate structure

Cyteir Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Cyteir Therapeutics, Inc.

  • BML Investment Partners, L.P. Filed SC 13G/A on Cyteir Therapeutics, Inc., latest Mar 19, 2024 (3 filings since Jan 26, 2023)
  • GAMCO Investors Filed SC 13D/A on Cyteir Therapeutics, Inc., latest Mar 12, 2024 (3 filings since Oct 19, 2023)
  • BAKER BROS. ADVISORS LP Filed SC 13G/A on Cyteir Therapeutics, Inc., latest Feb 14, 2024 (2 filings since Feb 14, 2023)
  • Lightstone Ventures II, L.P. Filed SC 13G/A on Cyteir Therapeutics, Inc., latest Feb 14, 2024 (2 filings since Feb 14, 2022)
  • Newtyn Management, LLC Filed SC 13G on Cyteir Therapeutics, Inc., latest Feb 14, 2024
  • Avidity Partners Management LP Filed SC 13G/A on Cyteir Therapeutics, Inc., latest Feb 13, 2024 (3 filings since Feb 14, 2022)
  • HEDGEHOG CAPITAL LLC Filed SC 13G/A on Cyteir Therapeutics, Inc., latest Jan 19, 2024 (2 filings since Nov 3, 2023)
  • Novo Holdings A/S Filed SC 13D/A on Cyteir Therapeutics, Inc., latest Aug 3, 2023 (5 filings since Dec 20, 2021)
  • FMR LLC Filed SC 13G/A on Cyteir Therapeutics, Inc., latest Jul 10, 2023 (4 filings since Oct 12, 2021)
  • Janus Henderson Group Ltd. Filed SC 13G/A on Cyteir Therapeutics, Inc., latest Feb 9, 2023 (2 filings since Feb 11, 2022)
  • Osage University GP II, LLC Filed SC 13G/A on Cyteir Therapeutics, Inc., latest Feb 2, 2023 (2 filings since Feb 3, 2022)
  • RA CAPITAL MANAGEMENT, L.P. Filed SC 13G/A on Cyteir Therapeutics, Inc., latest Aug 15, 2022 (2 filings since Feb 14, 2022)
  • Cyteir Therapeutics, Inc. Stoneham, Massachusetts

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Cyteir Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$3.5M4 Dec 31, 2022$3.2M4 Dec 31, 2021+9.7%
Accumulated depreciation$1.8M4 Dec 31, 2022$1.2M4 Dec 31, 2021+57.9%
Property and equipment, net$1.7M4 Dec 31, 2022$2.1M4 Dec 31, 2021−17.3%
Operating-lease assets (leased space)$2.1M4 Dec 31, 2022

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$147.1M4 Dec 31, 2022$189.7M4 Dec 31, 2021−22.5%

Leadership

Who has led Cyteir Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Markus Renschler Md.2022–2024

President

  1. Markus Renschler Md.2022–2024

Chief financial officer

  1. David G. Gaiero2023–2024
2025
Board members and other officers (16)

Timeline

  1. Mar 20, 20248-K Ended a material agreement; Change to shareholders' rights26
  2. Mar 7, 20248-K Listing notice or transfer; Other events27
  3. Dec 27, 20238-K Executive or director change28
  4. Dec 7, 20238-K Executive or director change29
  5. Dec 5, 20238-K Executive or director change30
  6. Nov 17, 20238-K Shareholder vote31
  7. Oct 12, 20238-K Other events32
  8. Oct 5, 20238-K Entered a material agreement33
  9. Jun 30, 20238-K Other events34
  10. Jun 14, 20238-K Shareholder vote35
  11. Jun 5, 20238-K Other events36
  12. Jun 2, 20238-K Executive or director change37
  13. Feb 24, 2022New chief executive Markus Renschler Md. becomes CEO9

Calendar

When it reported results

  1. May 10, 2023Reported quarterly or annual results38
  2. Mar 23, 2023Reported quarterly or annual results39
  3. Feb 3, 2023Reported quarterly or annual results40
  4. Nov 7, 2022Reported quarterly or annual results41
  5. Aug 8, 2022Reported quarterly or annual results42
  6. May 5, 2022Reported quarterly or annual results43

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

169 filings to the SEC since October 2021: 3 annual reports, 7 quarterly reports, 32 major events, 61 insider forms, 32 large holders, 34 other. The latest 20:

  1. Mar 29, 202415-12G EDGAR
  2. Mar 25, 20244 EDGAR
  3. Mar 21, 2024AW EDGAR
  4. Mar 21, 2024AW EDGAR
  5. Mar 21, 2024AW EDGAR
  6. Mar 21, 2024S-8 POS EDGAR
  7. Mar 21, 2024S-8 POS EDGAR
  8. Mar 21, 2024S-8 POS EDGAR
  9. Mar 20, 20248-K EDGAR
  10. Mar 19, 2024SC 13G/A EDGAR
  11. Mar 19, 20244 EDGAR
  12. Mar 19, 20243 EDGAR
  13. Mar 18, 202425 EDGAR
  14. Mar 18, 2024POS AM EDGAR
  15. Mar 18, 2024POS AM EDGAR
  16. Mar 18, 2024POS AM EDGAR
  17. Mar 13, 2024EFFECT EDGAR
  18. Mar 12, 2024POS AM EDGAR
  19. Mar 12, 2024SC 13D/A EDGAR
  20. Mar 7, 20248-K EDGAR

The 169 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

30 open-market trades by officers, directors and large owners since October 2021: 12 buys and 18 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 20, 2024Leonard Braden Michael10% ownerBuy170,589$2.95$503.2KForm 4
Mar 18, 2024Leonard Braden Michael10% ownerBuy113,777$3.01$342.5KForm 4
Jul 20, 2023Novo Holdings A/S10% ownerSale100,000$2.75$275.0KForm 4
Jul 19, 2023Novo Holdings A/S10% ownerSale1,900$2.76$5.2KForm 4
Jul 18, 2023Novo Holdings A/S10% ownerSale6,500$2.76$17.9KForm 4
Jul 17, 2023Novo Holdings A/S10% ownerSale21,100$2.75$58.0KForm 4
Jul 14, 2023Novo Holdings A/S10% ownerSale11,000$2.74$30.1KForm 4
Jun 30, 2023Novo Holdings A/S10% ownerSale200,937$2.63$528.5KForm 4
Jun 27, 2023Novo Holdings A/S10% ownerSale31,978$1.77$56.6KForm 4
Jun 26, 2023Novo Holdings A/S10% ownerSale8,437$1.79$15.1KForm 4
Jun 23, 2023Novo Holdings A/S10% ownerSale3,423$1.88$6.4KForm 4
Jun 22, 2023Novo Holdings A/S10% ownerSale5,041$1.94$9.8KForm 4
Jun 21, 2023Novo Holdings A/S10% ownerSale4,834$1.99$9.6KForm 4
Jun 20, 2023Novo Holdings A/S10% ownerSale744$2.11$1.6KForm 4
Jun 16, 2023Novo Holdings A/S10% ownerSale5,983$2.03$12.1KForm 4
Jun 15, 2023Novo Holdings A/S10% ownerSale10,002$2.03$20.3KForm 4
Jun 14, 2023Novo Holdings A/S10% ownerSale2,872$2.11$6.1KForm 4
Jun 13, 2023Novo Holdings A/S10% ownerSale2,626$2.10$5.5KForm 4
Jun 12, 2023Novo Holdings A/S10% ownerSale900$2.06$1.9KForm 4
Dec 7, 2022Zakrzewski Joseph SDirectorBuy21,202$1.30$27.6KForm 4

All 30 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Cyteir Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCyteir Therapeutics, Inc.1
  • CIK0001662244
  • Employer ID (EIN)45-54299011
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressP.O. Box 80084, Stoneham, MA 021801
  • Phone857-285-41401
  • Shares outstanding35,998,024 as of Aug 4, 20236
  • Public float$69.5M as of Jun 30, 20228
  • On EDGAR sinceDec 30, 20151
  • Filings221 in all: 4 (62), 8-K (34), 3 (19), SC 13G/A (14), SC 13G (11), 10-Q (8), SC 13D/A (7), UPLOAD (5)1
    All 39 form types

    144 (4), CORRESP (4), D (4), DEFA14A (4), POS AM (4), AW (3), EFFECT (3), S-8 (3), S-8 POS (3), 10-K (2), D/A (2), DEF 14A (2), DRS/A (2), DRSLTR (2), S-1/A (2), SC 13D (2), 10-K/A (1), 15-12G (1), 25 (1), 4/A (1), 424B3 (1), 424B4 (1), 8-A12B (1), 8-K/A (1), ARS (1), CERT (1), DEFM14A (1), DRS (1), PREM14A (1), S-1 (1), S-3 (1)

  • Latest filingsAnnual report (10-K) Mar 23, 2023
    Quarterly report (10-Q) Nov 6, 2023
    Proxy statement (DEF 14A) Apr 27, 2023
    Latest 8-K (8-K) Mar 20, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
    SEC EDGAROther events
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57